Daniel Brennan, an analyst from TD Cowen, maintained the Hold rating on Quanterix (QTRX – Research Report). The associated price target was lowered to $10.00.
Daniel Brennan has given his Hold rating due to a combination of factors influencing Quanterix’s current and future performance. The company’s recent guidance for 2025 sales was notably below consensus expectations, particularly due to anticipated declines in revenue from the US academic and government sectors. This has raised concerns about the company’s short-term financial outlook, despite management’s view that the slowdown is temporary.
Despite these challenges, Quanterix’s stock has already seen a significant decline, trading at a low enterprise value, which suggests that much of the negative sentiment is already reflected in the current stock price. Additionally, there are positive long-term drivers, such as potential benefits from Alzheimer’s data, FDA progress, and product advancements, which could enhance future growth. Therefore, while the immediate outlook is cautious, the potential for long-term value creation justifies a Hold rating.